1280 related articles for article (PubMed ID: 10839993)
21. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
22. Metformin modulates insulin post-receptor signaling transduction in chronically insulin-treated Hep G2 cells.
Yuan L; Ziegler R; Hamann A
Acta Pharmacol Sin; 2003 Jan; 24(1):55-60. PubMed ID: 12511230
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo.
Bates TE; Strangward M; Keelan J; Davey GP; Munro PM; Clark JB
Neuroreport; 1996 May; 7(8):1397-400. PubMed ID: 8856684
[TBL] [Abstract][Full Text] [Related]
24. Aroclor 1254 induced cytotoxicity and mitochondrial dysfunction in isolated rat hepatocytes.
Aly HA; Domènech O
Toxicology; 2009 Aug; 262(3):175-83. PubMed ID: 19486918
[TBL] [Abstract][Full Text] [Related]
25. Molecular action of metformin in hepatocytes: an updated insight.
Sliwinska A; Drzewoski J
Curr Diabetes Rev; 2015; 11(3):175-81. PubMed ID: 25808533
[TBL] [Abstract][Full Text] [Related]
26. Pro-oxidant mitochondrial matrix-targeted ubiquinone MitoQ10 acts as anti-oxidant at retarded electron transport or proton pumping within Complex I.
Plecitá-Hlavatá L; Jezek J; Jezek P
Int J Biochem Cell Biol; 2009; 41(8-9):1697-707. PubMed ID: 19433311
[TBL] [Abstract][Full Text] [Related]
27. Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression.
Sartoretto JL; Melo GA; Carvalho MH; Nigro D; Passaglia RT; Scavone C; Cuman RK; Fortes ZB
Life Sci; 2005 Oct; 77(21):2676-89. PubMed ID: 15964597
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of complex I by Ca2+ reduces electron transport activity and the rate of superoxide anion production in cardiac submitochondrial particles.
Matsuzaki S; Szweda LI
Biochemistry; 2007 Feb; 46(5):1350-7. PubMed ID: 17260964
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of phosphoenolpyruvate carboxykinase gene expression by metformin in cultured hepatocytes.
Yuan L; Ziegler R; Hamann A
Chin Med J (Engl); 2002 Dec; 115(12):1843-8. PubMed ID: 12622936
[TBL] [Abstract][Full Text] [Related]
30. [Inhibition of succinate and NADH oxidases of submitochondrial particles by iron chelators and sulfhydryl reagents].
Minkov IB; Myglova LM
Biokhimiia; 1979 May; 44(5):832-7. PubMed ID: 454713
[TBL] [Abstract][Full Text] [Related]
31. Anti-diabetic property of ethanolic extract of Andrographis paniculata in streptozotocin-diabetic rats.
Zhang XF; Tan BK
Acta Pharmacol Sin; 2000 Dec; 21(12):1157-64. PubMed ID: 11603293
[TBL] [Abstract][Full Text] [Related]
32. Establishment and characterization of a novel method for evaluating gluconeogenesis using hepatic cell lines, H4IIE and HepG2.
Okamoto T; Kanemoto N; Ban T; Sudo T; Nagano K; Niki I
Arch Biochem Biophys; 2009 Nov; 491(1-2):46-52. PubMed ID: 19799852
[TBL] [Abstract][Full Text] [Related]
33. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress.
Rösen P; Wiernsperger NF
Diabetes Metab Res Rev; 2006; 22(4):323-30. PubMed ID: 16444763
[TBL] [Abstract][Full Text] [Related]
34. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders.
Ben-Shachar D; Zuk R; Gazawi H; Ljubuncic P
Biochem Pharmacol; 2004 May; 67(10):1965-74. PubMed ID: 15130772
[TBL] [Abstract][Full Text] [Related]
35. A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate.
McCarty MF
Med Hypotheses; 1999 Feb; 52(2):89-93. PubMed ID: 10340287
[TBL] [Abstract][Full Text] [Related]
36. Hypoglycemic effect of isoleucine involves increased muscle glucose uptake and whole body glucose oxidation and decreased hepatic gluconeogenesis.
Doi M; Yamaoka I; Nakayama M; Sugahara K; Yoshizawa F
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1683-93. PubMed ID: 17299083
[TBL] [Abstract][Full Text] [Related]
37. Disruption of hepatic mitochondrial bioenergetics is not a primary mechanism for the toxicity of methoprene - relevance for toxicological assessment.
Monteiro JP; Oliveira PJ; Moreno AJ; Jurado AS
Chemosphere; 2008 Jul; 72(9):1347-54. PubMed ID: 18511104
[TBL] [Abstract][Full Text] [Related]
38. Attenuation of hepatic expression and secretion of selenoprotein P by metformin.
Speckmann B; Sies H; Steinbrenner H
Biochem Biophys Res Commun; 2009 Sep; 387(1):158-63. PubMed ID: 19576170
[TBL] [Abstract][Full Text] [Related]
39. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.
El-Mir MY; Nogueira V; Fontaine E; Avéret N; Rigoulet M; Leverve X
J Biol Chem; 2000 Jan; 275(1):223-8. PubMed ID: 10617608
[TBL] [Abstract][Full Text] [Related]
40. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study.
Guigas B; Detaille D; Chauvin C; Batandier C; De Oliveira F; Fontaine E; Leverve X
Biochem J; 2004 Sep; 382(Pt 3):877-84. PubMed ID: 15175014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
